Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Res Notes
Autors principals: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://ncbi.nlm.nih.gov/pubmed/27677700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-016-2256-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars